Treating Adolescents With Vitiligo: Adherence and Age Matter

In "Treating Adolescents With Vitiligo: Adherence and Age Matter," Dr. Lal explains how age, activity level, and adherence shape treatment choices for adolescent patients.

Dr. Lal addresses whether administration route changes his approach for adolescent patients. Most children, he notes, can swallow pills by around age eight, so he is not particularly concerned about oral therapy at age twelve. What matters more is a combination of factors: highly athletic children who sweat off topical medication are poor topical candidates and often do better on an oral agent, while comorbidities also factor into the decision. BSA restrictions frequently limit the choice regardless of preference. He finds that twelve-to-sixteen-year-olds tend to be less motivated, making a once-daily pill more realistic than twice-daily topical application, while patients over sixteen behave more like adults and can typically manage topical regimens within BSA limits. Ultimately, disease extent, severity, and location drive his decision more than age itself, since oral agents also take longer to show results.

Jason asks a follow-up about adherence, noting that payers commit to covering therapies knowing patients may see little response for a protracted period regardless of route. Dr. Lal responds that adherence hinges on setting expectations up front, emphasizing to families that treatment only makes sense if they will follow through. He finds pills generally outperform topicals for adherence, consistent with acne treatment data, though oral therapy still requires frequent follow-up every four to six months to reinforce compliance. Dr. Rosmarin adds that claims data confirm poor adherence across vitiligo treatments, since repigmentation takes far longer than for conditions like psoriasis or atopic dermatitis. Many patients quit within three months, before a fair trial is possible; he stresses that providers who set six-month expectations upfront see meaningfully better outcomes in practice.

Up next, in "Cross-Trial Vitiligo Data: What Payers Can and Can't Compare," the panel compares cross-trial data directly and discusses what payers can and cannot conclude from it.